6598 Stock Overview
Applied BioCode Corporation designs, develops, manufactures, and commercializes multiplex diagnostic testing products for the In-Vitro diagnostics market.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Applied BioCode Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$27.65 |
| 52 Week High | NT$37.65 |
| 52 Week Low | NT$23.20 |
| Beta | 0.47 |
| 1 Month Change | 0.36% |
| 3 Month Change | -1.60% |
| 1 Year Change | -20.55% |
| 3 Year Change | -74.63% |
| 5 Year Change | -33.21% |
| Change since IPO | -60.22% |
Recent News & Updates
Shareholder Returns
| 6598 | TW Medical Equipment | TW Market | |
|---|---|---|---|
| 7D | 1.1% | 0.3% | 2.0% |
| 1Y | -20.5% | 8.9% | 1.9% |
Return vs Industry: 6598 underperformed the TW Medical Equipment industry which returned 8.9% over the past year.
Return vs Market: 6598 underperformed the TW Market which returned 1.9% over the past year.
Price Volatility
| 6598 volatility | |
|---|---|
| 6598 Average Weekly Movement | 3.2% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in TW Market | 7.7% |
| 10% least volatile stocks in TW Market | 1.9% |
Stable Share Price: 6598 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 6598's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Chris Bernard | https://www.apbiocode.com |
Applied BioCode Corporation designs, develops, manufactures, and commercializes multiplex diagnostic testing products for the In-Vitro diagnostics market. The company’s products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the PCR amplification, hybridization, and detection steps of molecular testing; and the BioCode 2500 analyzer, a system that reads barcoded magnetic beads (BMB) and displays the barcode and fluorescence intensity for each BMB. In addition, It develops assays, such as BioCode SARS-CoV-2 Assay, a high volume automated nucleic acid multiplex assay for the detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs; BioCode Respiratory Pathogen Panels, which simultaneously detects and differentiates the presence of 17 respiratory pathogens in nasopharyngeal swabs; BioCode gastrointestinal (GI) pathogen panels for common GI pathogens, including viruses, bacteria, and parasites that cause infectious diarrhea; and MDx assays pipeline for various molecular tests.
Applied BioCode Corporation Fundamentals Summary
| 6598 fundamental statistics | |
|---|---|
| Market Cap | NT$2.25b |
| Earnings (TTM) | -NT$161.64m |
| Revenue (TTM) | NT$418.96m |
5.4x
P/S Ratio-14.0x
P/E RatioIs 6598 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6598 income statement (TTM) | |
|---|---|
| Revenue | NT$418.96m |
| Cost of Revenue | NT$154.69m |
| Gross Profit | NT$264.27m |
| Other Expenses | NT$425.91m |
| Earnings | -NT$161.64m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.98 |
| Gross Margin | 63.08% |
| Net Profit Margin | -38.58% |
| Debt/Equity Ratio | 0% |
How did 6598 perform over the long term?
See historical performance and comparison